Ethyl 8-methylimidazo[1,2-a]pyridine-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: Ethyl 8-methylimidazo[1,2-a]pyridine-3-carboxylate
• 英文别名: ethyl 8-methylimidazo[1,2-a]pyridine-3-carboxylate
• 化学式: C₁₁H₁₂N₂O₂
• 分子量: 204.22
• InChiKey: UBYPYDVJIQTHBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS<br/>[FR] NOUVEAUX AGONISTES DU RÉCEPTEUR DE SOMATOSTATINE DE SOUS-TYPE 4 (SSTR4)
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014184275A1

  公开（公告）日：2014-11-20

  The invention relates to 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.

  这项发明涉及一般式(I)的3-aza-双环[3.1.0]己烷-6-羧酸酰胺衍生物，它们是生长抑素受体亚型4（SSTR4）的激动剂，用于预防或治疗与SSTR4相关的医学疾病。此外，该发明涉及制备药物组合物的方法，以及根据该发明制备化合物的方法。
• [EN] ARYL AND HETEROARYL-FUSED TETRAHYDRO-1,4-OXAZEPINE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS<br/>[FR] TÉTRAHYDRO-1,4-OXAZÉPINE AMIDES FUSIONNÉES PAR ARYLE ET HÉTÉROARYLE EN TANT QU'AGONISTES DU RÉCEPTEUR DE LA SOMATOSTATINE DE SOUS-TYPE 4 (SSTR4)
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2016075239A1

  公开（公告）日：2016-05-19

  The invention relates to aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amide derivatives of general formula (l),which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates processes for manufacture of the compounds according to the invention.

  这项发明涉及一般式(l)的芳基和杂环芳基融合的四氢-1,4-噁唑啉酰胺衍生物，这些衍生物是生长抑素受体亚型4（SSTR4）的激动剂，可用于预防或治疗与SSTR4相关的医学疾病。此外，该发明涉及根据该发明制造化合物的工艺。
• [EN] MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS<br/>[FR] AMIDES DE MORPHOLINE ET DE 1,4-OXAZÉPANE UTILISÉS EN TANT QU'AGONISTES DU SOUS-TYPE 4 DU RÉCEPTEUR DE LA SOMATOSTATINE (SSTR4)
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2016075240A1

  公开（公告）日：2016-05-19

  The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.

  这项发明涉及一般式(I)的吗啡啶和1,4-噁唑烷酮酰胺衍生物，它们是生长抑素受体亚型4（SSTR4）的激动剂，用于预防或治疗与SSTR4相关的医学疾病。此外，该发明涉及制备药物组合物的方法，以及根据该发明制造化合物的方法。
• AZAHETEROARYL COMPOUND AND APPLICATION THEREOF
  申请人：Blueray Therapeutics (Shanghai) Co., Ltd

  公开号：EP4019521A1

  公开（公告）日：2022-06-29

  Disclosed in the present disclosure are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present disclosure also provides a method for preparing said compound, a composition containing said compound, and a use of said compound in the preparation of a drug for treating a disease or disorder related to the mechanism of action of an EED protein and/or a PRC2 protein complex. (Formula 1)

  本公开揭示了一种氮杂杂环化合物及其药学上可接受的盐和溶剂化物。本公开还提供了一种制备该化合物的方法、含有该化合物的组合物以及将该化合物用于制备用于治疗与EED蛋白和/或PRC2蛋白复合物作用机制相关的疾病或障碍的药物的用途。(式1)
• Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10071974B2

  公开（公告）日：2018-09-11

  The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.

  本发明涉及通式(I)的吗啉和1,4-氧氮杂环庚烷酰胺衍生物，它们是体生长抑素受体亚型4（SSTR4）的激动剂，可用于预防或治疗与SSTR4相关的疾病。此外，本发明还涉及制备药物组合物的工艺以及根据本发明制造化合物的工艺。